FDA Adverse Event Malfunction Summary report: N

I-STAT TROPONIN (CTNI) CARTRIDGE

MDR report key: 6769682 · Received August 5, 2017

Report

Report Number
2245578-2017-00247
Event Type
Malfunction
Date Received
August 5, 2017
Date of Event
October 27, 2016
Report Date
August 5, 2017
Manufacturer
ABBOTT POINT OF CARE
Product Code
MMI
UDI-DI
10054749001986
PMA / PMN Number
K031739
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
NJ, US
Reporter Occupation
OTHER HEALTH CARE PROFESSIONAL

Narratives

Additional Manufacturer Narrative · 1

(B)(4). APOC LABELING WAS EVALUATED DURING THE INVESTIGATION AS PERTAINING TO THE EVENT. THE INVESTIGATION WAS COMPLETED ON 02/16/2017. RETAIN PRODUCT WAS TESTED AND FUNCTIONING ACCORDING TO SPECIFICATION. RETURN PRODUCT WAS NOT AVAILABLE FOR INVESTIGATION. INVESTIGATION: A REVIEW OF THE DEVICE HISTORY RECORD CONFIRMED THAT THE CARTRIDGE LOT MET FINISHED GOODS RELEASE CRITERIA. RETAINED CARTRIDGE TESTING MET THE ACCEPTANCE CRITERIA OUTLINED IN APPENDIX 1 OF Q04.01.003 REV. Z (PRODUCT COMPLAINT LEVEL 2 AND LEVEL 3 INVESTIGATION PROCEDURE). NO DEFICIENCY HAS BEEN IDENTIFIED FOR CTNI CARTRIDGE LOT K16166. ASSESSMENT: BASED ON ONE I-STAT NEGATIVE RESULT AND THE RESULT FROM ANOTHER MANUFACTURER BEING CONSISTENTLY POSITIVE AND THE LIMITED PATIENT INFORMATION. THERE IS NOT ENOUGH INFORMATION TO DETERMINE WHETHER AN I-STAT PRODUCT MALFUNCTION OCCURRED. THE FDA GUIDANCE DOCUMENT (TROPONIN: WHAT LABORATORIANS SHOULD KNOW TO MANAGE ELEVATED RESULTS) CAUTIONS AGAINST COMPARING ASSAY RESULTS ACROSS TWO INSTRUMENT PLATFORMS. HAMA OR OTHER HETEROPHILE ANTIBODIES, MAY INTERFERE WITH IMMUNOASSAYS AND PRODUCE ERRONEOUS RESULTS AND THE MAGNITUDE OF THE INTERFERENCE MAY BE DIFFERENT BETWEEN PLATFORMS. AS PER THE PRODUCT LABELLING (CARTRIDGE AND TESTING INSTRUCTIONS-CTI SHEET), "RESULTS FROM THE I-STAT CTNI ASSAY SHOULD BE CONSIDERED IN THE CONTEXT OF THE ENTIRETY OF THE AVAILABLE CLINICAL INFORMATION." "AN ELEVATED TROPONIN VALUE ALONE IS NOT SUFFICIENT TO DIAGNOSE A MYOCARDIAL INFARCTION. RATHER, THE PATIENT'S CLINICAL PRESENTATION (HISTORY, PHYSICAL EXAM) AND ECG SHOULD BE USED IN CONJUNCTION WITH TROPONIN IN THE DIAGNOSTIC EVALUATION OF SUSPECTED MYOCARDIAL INFARCTION."

Description of Event or Problem · 1

ON (B)(6) 2016, ABBOTT POINT OF CARE (APOC) WAS CONTACTED BY A CUSTOMER REGARDING I-STAT TROPONIN CARTRIDGES THAT YIELDED A SUSPECTED DISCREPANT NEGATIVE RESULT OF 0.01 ON A (B)(6) MALE PATIENT. THE CUSTOMER REPORTED THE PATIENT WAS SENT TO THE CATH LAB BASE ON THE BECKMAN RESULTS. THERE WERE NO INJURIES ASSOCIATED WITH THIS EVENT. THERE WAS NO ADDITIONAL PATIENT INFORMATION AVAILABLE AT THE TIME OF THIS REPORT. RETURN PRODUCT AVAILABLE FOR INVESTIGATION. I-STAT RESULT 0.01; BECKMAN UNICEL DXI 1.13; RETESTED ON THE BECKMAN 1.02, 1.00. AT THE TIME OF THE EVENT THERE WAS NO INDICATION OF A PRODUCT MALFUNCTION BASED ON THE INFORMATION PROVIDED AND ASSESSED BY APOC, HOWEVER THIS MDR IS A RETROSPECTIVE FILING IN RESPONSE TO AN OBSERVATION FROM AN FDA INSPECTION CONDUCTED MAY 8TH TO 12TH, 2017 AT ABBOTT POINT OF CARE (B)(4).

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
549918 I-STAT TROPONIN (CTNI) CARTRIDGE CTNI CARTRIDGE MMI ABBOTT POINT OF CARE NA K16166 10054749001986

Patients

Seq Age Sex Outcome Treatment
1 45 YR